The transaction provides Genmab access to ProfoundBio’s ADC technology platforms.
These platforms are anticipated to complement Genmab’s existing suite of proprietary technology platforms, potentially leading to the creation of innovative medicines that could revolutionise cancer treatment and improve patient outcomes.
Genmab president and CEO Jan van de Winkel stated: “With the completion of this strategic transaction, we are excited to welcome our new colleagues and their expertise in developing next-generation antibody-drug conjugates to our exceptionally talented research and development team.
“We look forward to unlocking new opportunities as we strengthen our oncology portfolio and continue to work towards our goal of transforming the lives of patients with innovative antibody medicines.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.